A study conducted at the Los Angeles Children ‘s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).
Ichi chidzidzo (chemakumi maviri-gore huwandu hwehuwandu hwezvinyorwa zvesainzi) hwakawana kuti kurapwa kweMPAL ine yakaderera-chepfu regimen inosanganisirwa nerubatsiro rwakajeka rwekuregererwa uye nekugona kwenguva refu. Izvi zvakawanikwa zvakaburitswa muInternet magazini "Leukemia" muna Kukadzi 27, 2018.
MPAL accounts for 2% -5% of leukemia cases, which is historically difficult to treat, and the 5-year survival rate is less than 50%. The disease affects children and adults and is characterized by two common forms of leukemia: acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).
Chiremba anofanira kusarudza kuti oshandisa ZVEI kana AML, kana musanganiswa wenzira mbiri idzi. Iko hakuna kubvumirana kwakajeka kuti ndeipi nzira iri nani. Nekuti chirwere ichi hachiwanzoitika, zviuru zvevarwere hazvina kuongororwa kukiriniki kuti vaone chirongwa chakanakisa chekurapa. Pane kudaro, akawanda madiki, akasarudzika, uye anowanzo kupokana nyaya mishumo yakaburitswa mumagazini akaparadzirwa zvakapararira pasirese.
Kuti unzwisise zvirinani tsvagiridzo iripo uye nekupa vanachiremba nhungamiro yakajeka yekurapa, Orgel uye timu yekutsvagisa yeCLA vakaita ongororo yekutanga yakarongeka uye meta-ongororo yeMPAL. Chikwata ichi chakazopeta runyorwa kuva mapepa anokwana mazana maviri nemakumi maviri nemaviri kubva munyika makumi matatu nenhatu, zvinosanganisira varwere chiuru nemazana mana nemakumi mana nevapfumbamwe Kutsvaga kwavo kwakakosha: Varwere vakatanga kurapwa neZVESE (varwere vane chepfu hwakanyanya) vaive katatu kusvika kashanu mukana wekuwana kuregererwa kwakazara kupfuura varwere vaibatwa neAML. Varwere vakagamuchira kurapwa kwakasanganiswa vakaita zvakaipisisa.
Chidzidzo ichi chinosimbisa kukosha kwakakosha kwemiedzo yekiriniki kuona kurapwa kwakanakisa kweMPAL uye kunobatsira kusimudzira kurapwa kwechirwere ichi chisingawanzo.
